BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32437546)

  • 41. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
    Lopez AT; Bates S; Geskin L
    Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
    Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
    Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
    Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
    Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
    Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
    Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Phosphorylation of p21-activated Kinase 1 at Thr423 Induces Cell Cycle Arrest and Apoptosis in Cutaneous T-cell Lymphoma Cells.
    Wang Y; Li W; Zhang Q; Gu X; He X; Men Y; Zhang C
    Acta Derm Venereol; 2019 Oct; 99(11):1022-1028. PubMed ID: 31304555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What Is New in Cutaneous T Cell Lymphoma?
    Morgenroth S; Roggo A; Pawlik L; Dummer R; Ramelyte E
    Curr Oncol Rep; 2023 Nov; 25(11):1397-1408. PubMed ID: 37874473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
    Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
    EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
    Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
    J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.
    Vadivel CK; Willerslev-Olsen A; Namini MRJ; Zeng Z; Yan L; Danielsen M; Gluud M; Pallesen EMH; Wojewoda K; Osmancevic A; Hedebo S; Chang YT; Lindahl LM; Koralov SB; Geskin LJ; Bates SE; Iversen L; Litman T; Bech R; Wobser M; Guenova E; Kamstrup MR; Ødum N; Buus TB
    Blood; 2024 Apr; 143(15):1496-1512. PubMed ID: 38170178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
    Jain S; Washington A; Leaf RK; Bhargava P; Clark RA; Kupper TS; Stroopinsky D; Pyzer A; Cole L; Nahas M; Apel A; Rosenblatt J; Arnason J; Kufe D; Avigan D
    Mol Cancer Ther; 2017 Oct; 16(10):2304-2314. PubMed ID: 28729399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
    Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
    Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells.
    Zhang CL; Kamarashev J; Qin JZ; Burg G; Dummer R; Döbbeling U
    J Pathol; 2003 Jun; 200(2):249-54. PubMed ID: 12754746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
    Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic landscape of cutaneous T cell lymphoma.
    Choi J; Goh G; Walradt T; Hong BS; Bunick CG; Chen K; Bjornson RD; Maman Y; Wang T; Tordoff J; Carlson K; Overton JD; Liu KJ; Lewis JM; Devine L; Barbarotta L; Foss FM; Subtil A; Vonderheid EC; Edelson RL; Schatz DG; Boggon TJ; Girardi M; Lifton RP
    Nat Genet; 2015 Sep; 47(9):1011-9. PubMed ID: 26192916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
    Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
    Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
    Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
    J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.